Data from two phase I studies from Prelude Therapeutics Inc. helped open the American Association for Cancer Research virtual International Conference on Molecular Targets and Cancer Therapeutics on Oct. 7 but tugged the company’s stock sharply downward.
With its topical gel for primary axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 years of age and older, Brickell Biotech Inc. is gearing up to challenge Journey Medical Corp.’s Qbrexza (glycopyrronium), an anticholinergic agent contained in a single-use, pre-moistened, medicated cloth.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Brickell, Bristol Myers, Celltrion, Denali, G1, Genetx, Inhalon, Jounce, Minervax, Timber, Ultragenyx.
The start of a phase Ib/II trial with nanatinostat by Viracta Therapeutics Inc. has brought new attention to the burgeoning field of synthetic lethality, where a number of players are piquing the interest of Wall Street.
Privately held Retrotope Inc., the only company currently in the clinic studying the ultra-rare and fatal neurological disorder infantile neuroaxonal dystrophy, has new data it hopes to present to the FDA early next year.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim, Apexigen, Cassava, Covicept, Dialectic, Elicio, Entera, Legacy, Panther, Pharmather, Precirix, Takeda, Vaxart.
LONDON – Fixed and constant deep brain stimulation has been successful in treating Parkinson’s disease and epilepsy, but heterogeneity in individual response means that despite promise, clinical studies in serious depression have to date delivered inconsistent results. U.S. researchers have now developed a method for identifying the neural circuits underlying symptoms of depression in individual patients and applied this to deliver tailored therapy, using a commercially available device to stimulate the brain when these circuits are activated.
PARIS – M.A. Med Alliance SA (Medalliance), along with its Japanese partner MDK Medical, has completed enrollment following acceptance of a clinical trial notification from the Japanese Pharmaceutical Products and Medical Device Agency (PMDA) in June 2020.
DUBLIN – Redhill Biopharma Inc. is claiming a 62% relative reduction in day 42 mortality from COVID-19 among hospitalized severe patients who received its oral drug, opaganib, as compared with those on placebo. It is also reporting a shorter median time to discharge (10 days vs. 14 days) and a higher proportion of patients on treatment being able to breathe unassisted by day 14 (77% vs. 63.5%).